Treatment of hepatocellular carcinoma by injection of iodine*131-labelled lipiodol into the hepatic artery.

dc.contributor.authorPrabhasavat, Krisdee
dc.contributor.authorKruatrachue, Chutakiat
dc.contributor.authorChaiteerasuwet, Somyot
dc.contributor.authorDanpukdee, Kanjana
dc.contributor.authorVanpruks, Sajor
dc.contributor.authorTongdee, Trongtum
dc.contributor.authorPleehachinda, Rudee
dc.contributor.authorPusuwan, Pawana
dc.contributor.authorBuranapong, Puangrat
dc.contributor.authorManathathit, Sathapron
dc.contributor.authorSomchaitprasert, Pannee
dc.contributor.authorChaudakshetrin, Pschee
dc.date.accessioned2012-04-16T08:49:07Z
dc.date.available2012-04-16T08:49:07Z
dc.date.issued1998-12
dc.description.abstractThe therapeutic efficacy iodine*131-labelled Lipiodol was studies in the treatment of hepatocellular carcinoma (HCC). The results of the treatment were evaluated for four aspects: size of the tumour; serum alphafetoprotein level ; the quality of the patient’s life;and the survival rate. The hepatocellular carcinoma was diagnosed by evidence of mass in the liver using either computed tomography or ultrasonography with tissue biopsy and/or a high level of alphafetoprotein of more than 500 U. Twenty patients were randomized into two groups for comparison. The patients in group A were treated by intrahepatic injection of iodine*131-labelled Lipiodol 60 miliCuries(mCi). The patients in group B were treated by intra-hepatic injection of a mixture of Lipiodol and chemotherapeutic agents, mitomicin c 20 mg. and 5-fluoracil 500 mg., followed by selective hepatic artery embolisation of small pieces of gelatin sponge (gelfoam). Both groups were evaluated by computed tomography (CT) and the possible repeat of treatment protocol after two months. There were no serious side-effects or major complications in either group of patients. The patients’ conditions worsened by 40 percent in both groups. The tomours’ sizes remained unchanged by 50 percent in both groups. The serum alphafetoprotein levels had increased by 40 percent in group A, and remained unchanged by 50 percent in group B. The survival rates at one and two years in group A were 20 and 20 percent, and in group B there were 30 and 0 percent, respectively. Satisfactory results were obtained in the treatment of small HCC, size less than 5 cm. with intra-hepatic artery injection of iodine*131-labelled Lipiodol. In large HCC (>10cm) no response by the tumour was seen in either group. This was the first study of this type performed in Thailand.en_US
dc.identifier.citationPrabhasavat Krisdee, Kruatrachue Chutakiat, Chaiteerasuwet Somyot, Danpukdee Kanjana, Vanpruks Sajor, Tongdee Trongtum, Pleehachinda Rudee, Pusuwan Pawana, Buranapong Puangrat, Chaudakshetrin Pachee, Manathathit Sathapron, Somchaitprasert Pannee. Treatment of hepatocellular carcinoma by injection of iodine*131-labelled lipiodol into the hepatic artery. Siriraj Medical Journal, 1998 Dec; 50(12): 1158-1167.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/137675
dc.language.isoenen_US
dc.source.urihttps://www.sirirajmedj.com/content_download.php?content_id=696en_US
dc.subjectTreatmenten_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectInjection of iodine*131-labelled lipiodolen_US
dc.subjectHepatic arteryen_US
dc.titleTreatment of hepatocellular carcinoma by injection of iodine*131-labelled lipiodol into the hepatic artery.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
smj1998v50n12p1158.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Journal article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: